rabbit anti metap2  (Proteintech)

Journal: AMB Express

Article Title: Treponema pallidum inhibits CD4+ T-cell proliferation through METAP2: insights from Mendelian randomization analysis

doi: 10.1186/s13568-025-01940-3

Figure Lengend Snippet: METAP2 as a potential key molecule in regulating CD4 + T-cells in NS. A Venn diagram showing the overlap between cis-proteins from rQTLs identified via mediation analysis and RNA-seq data from CD4 + T-cells of NS patients ( GSE103599 ). B The relationships between DelncRNAs and DEmiRNAs identified in GSE103599 and GSE156421 were determined via the starBase v3.0 database. The interactions between DEmiRNAs and METAP2 were predicted via TargetScan, miRcode, and MiRanda. On the basis of the predicted interactions among lncRNAs, miRNAs, and mRNAs, a ceRNA regulatory network was constructed and visualized via Cytoscape 3.10.2. C qRT‒PCR analysis was used to detect changes in the mRNA expression levels of LINC00501, LINC00334, METAP2, and PDCD5 in Jurkat T-cells treated with LTP, DTP, or PBS for 24 h. D Western blotting was performed to assess changes in the protein expression levels of METAP2 and PDCD5 in Jurkat T-cells treated with LTP, DTP, or PBS for 24 h. * p < 0.05; ** p < 0.01; *** p < 0.001; ns, not significant

Article Snippet: The membranes were blocked with 5% nonfat dry milk and incubated overnight at 4 °C with antibodies against METAP2 (#sc-365637, Santa Cruz Biotechnology), PDCD5 (#YN1785, Immunoway), and ACTB (#sc-47778, Santa Cruz Biotechnology).

Techniques: RNA Sequencing, Construct, Expressing, Western Blot

Journal: AMB Express

Article Title: Treponema pallidum inhibits CD4+ T-cell proliferation through METAP2: insights from Mendelian randomization analysis

doi: 10.1186/s13568-025-01940-3

Figure Lengend Snippet: T. pallidum inhibits CD4 + T-cell proliferation through METAP2. A-D qRT-PCR and Western blotting were used to measure METAP2 mRNA and protein expression levels in Jurkat T-cells 48 h after METAP2 knockdown or overexpression to assess the transfection efficacy. E , F Flow cytometry was used to assess Ki67 levels to evaluate the impact of METAP2 gene knockdown or overexpression on Jurkat T-cell proliferation. G Flow cytometry was used to determine Ki67 levels to assess the effects of METAP2 overexpression and T. pallidum treatment on Jurkat T-cell proliferation. ** p < 0.01; *** p < 0.001; ns, not significant

Article Snippet: The membranes were blocked with 5% nonfat dry milk and incubated overnight at 4 °C with antibodies against METAP2 (#sc-365637, Santa Cruz Biotechnology), PDCD5 (#YN1785, Immunoway), and ACTB (#sc-47778, Santa Cruz Biotechnology).

Techniques: Quantitative RT-PCR, Western Blot, Expressing, Knockdown, Over Expression, Transfection, Flow Cytometry

Journal: Cancer Research Communications

Article Title: A phase 1 safety study of evexomostat (SDX-7320) in late-stage cancer patients: an anti-angiogenic, insulin-sensitizing drug conjugate targeting MetAP2

doi: 10.1158/2767-9764.crc-24-0627

Figure Lengend Snippet: FIGURE 1 METAP2 inhibition measured in whole blood following

Article Snippet: The authors acknowledge the contributions of Dr. Melissa Johnson (Sarah Cannon Research Institute), Dr. Johanna C. Bendell (currently, Roche) and Dr. Jasgit Sachdev (currently, Ideaya Biosciences) for patient enrollment and Joeseph Johnson (Exosome Diagnostics) for ex vivo METAP2 assay development.

Techniques: Inhibition